Dee Datta

Dee Datta, Ph.D., is co-founder and CEO of Switch Therapeutics, a San Francisco-based biotechnology company pioneering conditionally activated siRNA (CASi) molecules to treat neurodegenerative diseases and other conditions with significant unmet need. With a PhD from Caltech, an MBA from Stanford, and a career spanning venture capital at The Column Group and Longitude Capital, corporate development at Forty Seven Inc., and the C-suite at XOMA, Datta brings rare scientific depth and dealmaking fluency to one of the most ambitious RNA medicine platforms in the field. Switch raised a $52 million Series A in March 2023 and in late 2024 named its first development candidate - CASi-APOE, a brain-targeted, liver-sparing RNAi therapy aimed at the 60% of Alzheimer's patients who carry the APOE4 gene variant.